Solu was founded in 2022 with a mission to revolutionize the world of bacterial DNA analysis. We are headquartered in Helsinki, Finland.
Solu raised a pre-seed financing round in early 2023, led by Lifeline Ventures.
We work with leading medical professionals, researchers, and universities to uncover new insights into microbes that can enable new diagnostics, therapies and health policies.
Our technology has potential to avoid unnecessary deaths from resistant infections. With better understanding of pathogens, faster diagnostics, and robust surveillance, Solu paves the way for developing new therapies, such as antibiotics, bacteriophages and antitoxin agents.
Our team is passionate about making genomics accessible and we want to partner with you to create a better future for healthcare. Let's work together to tackle antibiotic resistance and improve global health.